A phase 1 study of obinutuzumab induction followed by 2 years of maintenance in patients with relapsed CD20-positive B-cell malignancies.

No abstract is available for this paper.

• Publication year

  2012

• Venue

  Blood

• Publication date

  2012-05-31

• Fields of study

  Medicine

• Identifiers
  DOI 10.1182/blood-2012-02-408773PMID 22438256
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Epitope characterization and crystal structure of GA101 provide insights into the molecular basis for type I/II distinction of CD20 antibodies.

  2011cited by this paper
• Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial.

  2011cited by this paper
• CD20 antibodies: doing the time warp.

  2011cited by this paper
• and immune effector cellmediated B-cell cytotoxicity engineering of a new type II anti-CD20 antibody with enhanced direct Increasing the efficacy of CD20 antibody therapy through the

  2010cited by this paper
• Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte.

  2010cited by this paper
• Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity.

  2010cited by this paper
• Rituximab plus fludarabine and cyclophosphamide prolongs progression-free survival compared with fludarabine and cyclophosphamide alone in previously treated chronic lymphocytic leukemia.

  2010cited by this paper
• Rituximab maintenance treatment of relapsed/resistant follicular non-Hodgkin's lymphoma: long-term outcome of the EORTC 20981 phase III randomized intergroup study.

  2010cited by this paper
• Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial.

  2010cited by this paper
• Phase I Study of RO5072759 (GA101) in Relapsed/Refractory Chronic Lymphocytic Leukemia.

  2009cited by this paper
• Phase I Study of RO5072759 (GA101) in Patients with Relapsed/Refractory CD20+ Non-Hodgkin Lymphoma (NHL).

  2009cited by this paper
• Maintenance rituximab after cyclophosphamide, vincristine, and prednisone prolongs progression-free survival in advanced indolent lymphoma: results of the randomized phase III ECOG1496 Study.

  2009cited by this paper
• GA-101, a third-generation, humanized and glyco-engineered anti-CD20 mAb for the treatment of B-cell lymphoid malignancies.

  2009cited by this paper
• Phase III study of R-CVP compared with cyclophosphamide, vincristine, and prednisone alone in patients with previously untreated advanced follicular lymphoma.

  2008cited by this paper
• Rituximab combined with chemotherapy and interferon in follicular lymphoma patients: results of the GELA-GOELAMS FL2000 study.

  2008cited by this paper
• Rituximab added to first-line mitoxantrone, chlorambucil, and prednisolone chemotherapy followed by interferon maintenance prolongs survival in patients with advanced follicular lymphoma: an East German Study Group Hematology and Oncology Study.

  2007cited by this paper
• Evaluation of the Rituximab Maintenance Improves Clinical Outcome of Relapsed/Resistant Follicular Non-Hodgkin's Lymphoma,Both in Patients with and without Rituximab during Induction:Results of A Prospective Randomized Phase III Intergroup Trial

  2007cited by this paper
• Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma.

  2006cited by this paper
• Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: results of a prospective randomized phase 3 intergroup trial.

  2006cited by this paper
• Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of t

  2005cited by this paper
• Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia.

  2005cited by this paper
• Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly x 4 schedule.

  2004cited by this paper
• CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment.

  2003cited by this paper
• Rituximab as first-line and maintenance therapy for patients with indolent non-hodgkin's lymphoma.

  2002cited by this paper
• Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group.

  1999cited by this paper
• National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment.

  1996cited by this paper

• Development of Nomogram for Predicting the Overall Survival of Diffuse Large B-Cell Lymphoma (DLBCL) Patients Based on Clinical Data and Systemic Inflammation Markers

  2025cites this paper
• Single-Agent and Associated Therapies with Monoclonal Antibodies: What About Follicular Lymphoma?

  2025cites this paper
• Biomarkers and coptis chinensis activity for rituximab-resistant diffuse large B-cell lymphoma: Combination of bioinformatics analysis, network pharmacology and molecular docking

  2024cites this paper
• Zelluläre Therapien im Alter: Everything, everywhere, all at once?

  2024cites this paper
• Maintenance therapy for chronic lymphocytic leukaemia.

  2024cites this paper
• Obinutuzumab in the treatment of B-cell malignancies: a comprehensive review

  2022cites this paper
• Comparative analysis of rituximab or obinutuzumab combined with CHOP in first-line treatment of follicular lymphoma

  2022cites this paper
• Challenges and Opportunities for the Large-Scale Chemoenzymatic Glycoengineering of Therapeutic N-Glycosylated Monoclonal Antibodies

  2022cites this paper
• Obinutuzumab in Kidney Transplantation: Effect on B-cell Counts and Crossmatch Tests.

  2021cites this paper
• Long-term activity of tandem CD19/CD20 CAR therapy in refractory/relapsed B-cell lymphoma: a single-arm, phase 1–2 trial

  2021cites this paper
• Importance and Monitoring of Therapeutic Immunoglobulin G Glycosylation.

  2021cites this paper
• Inpatient treatment of relapsed/refractory diffuse large B-cell lymphoma (r/r DLBCL): A health economic perspective.

  2021cites this paper
• Chapter 1: Monoclonal Antibodies: Structure, Physicochemical Stability, and Protein Engineering

  2020cites this paper
• Impact of maintenance rituximab on duration of response in primary central nervous system lymphoma

  2020cites this paper
• Phase II trial evaluating the efficacy and safety of the anti-CD20 monoclonal antibody obinutuzumab in patients with marginal zone lymphoma.

  2020cites this paper
• CAR-T treatment for hematological malignancies

  2020cites this paper
• Anti-CD20 treatment for B-cell malignancies: current status and future directions

  2020cites this paper
• Improving CD20 antibody therapy: obinutuzumab in lymphoproliferative disorders

  2019cites this paper
• Antibody Therapy in Follicular Lymphoma

  2019cites this paper
• Ibrutinib reduces obinutuzumab infusion-related reactions in patients with chronic lymphocytic leukemia and is associated with changes in plasma cytokine levels

  2019influential citation
• Pharmacokinetics, exposure, efficacy and safety of obinutuzumab in rituximab‐refractory follicular lymphoma patients in the GADOLIN phase III study

  2019cites this paper
• Site-specific N-glycan Analysis of Antibody-binding Fc γ Receptors from Primary Human Monocytes*

  2019cites this paper
• Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B‐Cell Lymphoma

  2019cites this paper
• Obinutuzumab combined with lenalidomide for relapsed or refractory follicular B-cell lymphoma (GALEN): a multicentre, single-arm, phase 2 study.

  2019cites this paper
• An open-label phase 1b study of obinutuzumab plus lenalidomide in relapsed/refractory follicular B-cell lymphoma.

  2018cites this paper
• Chronic lymphocytic leukemia and infection risk in the era of targeted therapies: Linking mechanisms with infections.

  2018cites this paper
• Anti-CD20 Directed Therapy of B Cell Lymphomas: Are New Agents Really Better?

  2018cites this paper
• Renal involvement in chronic lymphocytic leukemia

  2018cites this paper
• A tale of two antibodies: obinutuzumab versus rituximab

  2018cites this paper
• Discovery and Development of Obinutuzumab (GAZYVA, GAZYVARO), a Glycoengineered Type II Anti‐CD20 Antibody for the Treatment of Non‐Hodgkin Lymphoma and Chronic Lymphocytic Leukemia

  2018cites this paper
• Obinutuzumab for the treatment of chronic lymphocytic leukemia and other B-cell lymphoproliferative disorders

  2017cites this paper
• Impact of obinutuzumab alone and in combination for follicular lymphoma

  2017cites this paper
• Managing Tumor Lysis Syndrome in the Era of Novel Cancer Therapies

  2017cites this paper
• Role for ZAP-70 Signaling in the Differential Effector Functions of Rituximab and Obinutuzumab (GA101) in Chronic Lymphocytic Leukemia B Cells

  2017cites this paper
• Tumor Lysis Syndrome in Chronic Lymphocytic Leukemia with Novel Targeted Agents

  2017cites this paper
• Possible novel agents in marginal zone lymphoma.

  2017cites this paper
• Obinutuzumab‐induced serum sickness following salvage therapy for chronic lymphocytic leukemia

  2017cites this paper
• Treatment approaches of hard-to-treat non-Hodgkin lymphomas

  2017cites this paper
• Lymphocytic Leukemia B Cells Obinutuzumab ( GA 101 ) in Chronic Effector Functions of Rituximab and Role for ZAP-70 Signaling in the Differential

  2017cites this paper
• Rituximab in the treatment of follicular lymphoma: the future of biosimilars in the evolving therapeutic landscape

  2017cites this paper
• Glycosylation engineering of therapeutic IgG antibodies: challenges for the safety, functionality and efficacy

  2017cites this paper
• Case Report: SLL/CLL Associated With Paraneoplastic Hyperimmunoglobulinemia and Vasculitic Skin Lesions

  2017cites this paper
• Combination therapy with the type II anti-CD20 antibody obinutuzumab

  2017cites this paper
• Chronic lymphocytic leukemia therapy: new targeted therapies on the way

  2016cites this paper
• Managing Infusion-Related Reactions for Patients With Chronic Lymphocytic Leukemia Receiving Obinutuzumab.

  2016cites this paper
• Obinutuzumab in follicular lymphoma.

  2016cites this paper
• Safety and efficacy of obinutuzumab with CHOP or bendamustine in previously untreated follicular lymphoma

  2016cites this paper
• Anti-CD20 monoclonal antibodies in chronic lymphocytic leukemia: from uncertainties to promises.

  2016cites this paper
• Obinutuzumab for relapsed or refractory indolent non-Hodgkin’s lymphomas

  2016cites this paper
• Obinutuzumab for the treatment of indolent lymphoma.

  2016cites this paper
• Obinutuzumab plus bendamustine versus bendamustine monotherapy in patients with rituximab-refractory indolent non-Hodgkin lymphoma (GADOLIN): a randomised, controlled, open-label, multicentre, phase 3 trial.

  2016cites this paper
• Tumor lysis syndrome in the era of novel and targeted agents in patients with hematologic malignancies: a systematic review

  2016cites this paper
• Novel Immunotherapies for B-Cell Lymphomas and Leukemias.

  2016cites this paper
• Allografts for Follicular Non-Hodgkin Lymphoma: Why Never Is No Longer an Acceptable Answer.

  2016cites this paper
• Treating chronic lymphocytic leukemia with obinutuzumab: safety and efficacy considerations

  2016influential citation
• The safety profile of monoclonal antibodies for chronic lymphocytic leukemia

  2016influential citation
• Rationale for optimal obinutuzumab/GA101 dosing regimen in B-cell non-Hodgkin lymphoma

  2016cites this paper
• Novel agents in follicular lymphoma: choosing the best target.

  2016cites this paper
• A Review of Obinutuzumab (GA101), a Novel Type II Anti-CD20 Monoclonal Antibody, for the Treatment of Patients with B-Cell Malignancies

  2016cites this paper
• A review of monoclonal antibody therapies in lymphoma.

  2016cites this paper
• Randomized Phase II Trial Comparing Obinutuzumab (GA101) With Rituximab in Patients With Relapsed CD20+ Indolent B-Cell Non-Hodgkin Lymphoma: Final Analysis of the GAUSS Study.

  2015cites this paper
• Obinutuzumab treatment in the elderly patient with chronic lymphocytic leukemia

  2015cites this paper
• Disseminated Enteroviral Infection Associated with Obinutuzumab

  2015cites this paper
• New developments in the treatment of chronic lymphocytic leukemia: role of obinutuzumab

  2015cites this paper
• Cytokine release in patients with CLL treated with obinutuzumab and possible relationship with infusion-related reactions.

  2015cites this paper
• Chemotherapy-free treatment in patients with follicular lymphoma

  2015cites this paper
• Novel Targeted Agents in Hodgkin and Non-Hodgkin Lymphoma Therapy

  2015cites this paper
• Investigational therapies targeting lymphocyte antigens for the treatment of non-Hodgkin’s lymphoma

  2015cites this paper
• NK Cell-Mediated Antibody-Dependent Cellular Cytotoxicity in Cancer Immunotherapy

  2015cites this paper
• Obinutuzumab plus fl udarabine / cyclophosphamide or bendamustine in the initial therapy of CLL patients : the phase 1 b GALTON trial

  2015cites this paper
• Obinutuzumab for the treatment of patients with previously untreated chronic lymphocytic leukemia: overview and perspective

  2015cites this paper
• Obinutuzumab in hematologic malignancies: lessons learned to date.

  2015influential citation
• Obinutuzumab (GA101) for the Treatment of Chronic Lymphocytic Leukemia and Other B-Cell Non-Hodgkin's Lymphomas: A Glycoengineered Type II CD20 Antibody

  2015cites this paper
• Role of obinutuzumab in the treatment of chronic lymphocytic leukemia.

  2015cites this paper
• Three newly approved drugs for chronic lymphocytic leukemia: incorporating ibrutinib, idelalisib, and obinutuzumab into clinical practice.

  2015cites this paper
• Obinutuzumab: A Review of Its Use in Patients with Chronic Lymphocytic Leukaemia

  2015cites this paper
• Obinutuzumab plus fludarabine/cyclophosphamide or bendamustine in the initial therapy of CLL patients: the phase 1b GALTON trial.

  2015cites this paper
• Progress in the treatment of elderly/unfit chronic lymphocytic leukemia patients: results of the German CLL-11 trial

  2015cites this paper
• Obinutuzumab: its use in the management of chronic lymphocytic leukemia

  2015cites this paper
• Therapeutic targets and investigated strategies for treating B-cell non-Hodgkin lymphoma

  2015cites this paper
• Obinutuzumab jako nowa szansa terapeutyczna dla chorych na przewlekłą białaczkę limfocytową

  2015influential citation
• Novel Generation of Antibody-Based Therapeutics

  2015cites this paper
• Obinutuzumab in chronic lymphocytic leukemia.

  2015cites this paper
• New developments in the treatment of chronic lymphocytic leukemia: role of obinutuzumab

  2015cites this paper
• Drug Monographs: Afatinib and Obinutuzumab

  2014cites this paper
• The risk of infections in hematologic patients treated with rituximab is not influenced by cumulative rituximab dosage - a single center experience

  2014cites this paper
• Personalized medicine in CLL: current status and future perspectives.

  2014cites this paper
• Obinutuzumab for B-cell malignancies

  2014cites this paper
• Engineering more efficacious antibody therapy for myeloma.

  2014cites this paper
• Update on obinutuzumab in the treatment of B-cell malignancies

  2014cites this paper
• Accelerated therapeutic progress in diffuse large B cell lymphoma

  2014cites this paper
• Concise Review of Obinutuzumab in the Treatment of Patients with Chronic Lymphocytic Leukemia

  2014cites this paper
• Obinutuzumab (GA101) in relapsed/refractory chronic lymphocytic leukemia: final data from the phase 1/2 GAUGUIN study.

  2014cites this paper
• Chronic lymphocytic leukemia ( Cll ) aNti-CD 20 aNtibODies fOr patieNts with COmOrbiDities

  2014cites this paper
• A(nother) RAF mutation in LCH.

  2014cites this paper
• Cancer Chemotherapy Update Drug Monographs: Afatinib and Obinutuzumab

  2014cites this paper
• Rituximab and Other New Anti-CD20 MAbs for Non-Hodgkin’s Lymphoma Treatment

  2014cites this paper
• Immunotherapy in pediatric malignancies: current status and future perspectives.

  2014cites this paper
• This information is current as Phagocytosis and Cytotoxicity Enhances Monocyte / Macrophage-Mediated Glycoengineering of Therapeutic Antibodies Gerdes

  2014cites this paper
• Glycoengineering of Therapeutic Antibodies Enhances Monocyte/Macrophage-Mediated Phagocytosis and Cytotoxicity

  2014cites this paper